Thompson and Thompson Genetics and Genomics in Medicine Includes OGM in Latest Edition, Notes Workflow’s Performance and Ability to Detect More SVs than LRS at Lower Cost
02 November 2023 - 11:00PM
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that
optical genome mapping (OGM) was included for the first time in
Thompson and Thompson Genetics and Genomics in Medicine, 9th
edition, a textbook regularly used for medical students, genetic
counseling students, students in laboratory medicine, and more
advanced trainees pursuing American Board of Medical Genetics and
Genomics (ABMGG) residency and laboratory fellowships in clinical
biochemical genetics, laboratory genetics and genomics, and
clinical molecular genetics. The publication, which was last
updated in 2015, includes information on new discoveries in the
fields of genetics and genomics, the latest technologies in genome
analysis, and new diagnoses these methods can enable.
The book’s authors describe OGM as a powerful tool for genome
analysis, due to its ability to detect and validate structural
variants (SVs) that sequencing techniques may miss. They also note
that, when compared to long-read sequencing (LRS), OGM can be less
expensive and can resolve complex SVs with greater precision,
showing its potential as a tool in clinical research
investigations.
“We are thrilled to see OGM included in the newest edition of
Thompson and Thompson Genetics and Genomics in Medicine, which is
the primary training manual for trainees and fellows seeking ABMGG
certifications in clinical biochemical genetics, laboratory
genetics and genomics, and clinical molecular genetics. The book
plays an important role in directing the genomics community toward
emerging techniques, and in comparing different methods of genome
analysis,” commented Alka Chaubey, PhD, FACMG, chief medical
officer of Bionano.
“Inclusion in this book is a significant milestone for OGM and
for people in the various fields of genome analysis who are looking
for ways to move the community forward. We were pleased to see
the authors note OGM’s ability to detect clinically relevant
SVs that other methods, including LRS, miss, while citing OGM’s
potential lower cost and greater accuracy, particularly as the
SVs detected by OGM in research may ultimately lead to
improved diagnosis and detection of genetic disorders,”
added Erik Holmlin, PhD, president and chief executive
officer of Bionano.
The publication can be found here.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis technology. For more information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s OGM products
are for research use only and not for use in diagnostic
procedures.
Forward-Looking Statements of
Bionano
This press release contains forward-looking statements contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “can,”
“may,” “potential” and similar expressions (as well as other words
or expressions referencing future events, conditions or
circumstances and the negatives thereof) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the potential of OGM to reveal SVs that sequencing techniques may
miss; the potential of OGM to resolve complex SVs with greater
precision and less expensively when compared to LRS; the potential
of OGM as a tool in clinical research investigations; and other
statements that are not historical facts.
Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of geopolitical
and macroeconomic developments, such as recent and future bank
failures, the ongoing Ukraine-Russia conflict, related sanctions,
the Israel-Hamas war, and any global pandemics, on our business and
the global economy; challenges inherent in developing,
manufacturing and commercializing products; our ability to further
deploy new products and applications and expand the markets for our
technology platforms; failure of our OGM solutions to be adopted as
a tool in clinical research investigations; the failure of OGM to
detect SVs that sequencing technologies miss; the failure of OGM to
detect SVs more precisely or less expensively when compared to LRS;
; future publications that contradict or do not support the
statements in the newest edition of Thompson and Thompson Genetics
and Genomics in Medicine; our expectations and beliefs regarding
future growth of the business and the markets in which we operate;
changes in our strategic and commercial plans; our ability to
obtain sufficient financing to fund our strategic plans and
commercialization efforts and our ability to continue as a “going
concern”; and including the risks and uncertainties described in
our filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2022 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We are under no duty to
update any of these forward-looking statements after the date they
are made to conform these statements to actual results or revised
expectations, except as required by law. You should, therefore, not
rely on these forward-looking statements as representing our views
as of any date subsequent to the date the statements are made.
Moreover, except as required by law, neither we nor any other
person assumes responsibility for the accuracy and completeness of
the forward-looking statements contained in this press release.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2024 to May 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2023 to May 2024